{"id":"revaprazan","rwe":[{"pmid":"41213274","year":"2025","title":"A Novel UPLC-MS/MS Method for Determining Tegoprazan in Rat Plasma: An Application in a Rat Pharmacokinetic Study.","finding":"","journal":"Biomedical chromatography : BMC","studyType":"Clinical Study"},{"pmid":"41194018","year":"2025","title":"In vitro combination effects and mechanisms of Revaprazan with Triazole antifungal drugs on Aspergillus.","finding":"","journal":"BMC microbiology","studyType":"Clinical Study"},{"pmid":"40697654","year":"2025","title":"Clinical pharmacokinetics of potassium competitive acid blockers: a systematic review and meta-analysis.","finding":"","journal":"Frontiers in pharmacology","studyType":"Clinical Study"},{"pmid":"40296472","year":"2025","title":"Preliminary Analysis of Drug-Induced Ototoxicity in South Korea: Trends From a National Sample Dataset.","finding":"","journal":"Journal of audiology & otology","studyType":"Clinical Study"},{"pmid":"41341971","year":"2024","title":"[Impact of P-CABs in the Treatment of Acid-related Diseases: an Evidence Review].","finding":"","journal":"Acta gastroenterologica Latinoamericana","studyType":"Clinical Study"}],"tags":[{"label":"revaprazan","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Potassium-transporting ATPase","category":"target"},{"label":"ATP4A","category":"gene"},{"label":"ATP4B","category":"gene"},{"label":"Active","category":"status"},{"label":"Duodenal ulcer disease","category":"indication"},{"label":"Gastric ulcer","category":"indication"},{"label":"Gastro-esophageal reflux disease with esophagitis","category":"indication"}],"phase":"marketed","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=REVAPRAZAN","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:56:34.910929+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:56:41.105276+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=REVAPRAZAN","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:56:41.436086+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1618279/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:56:42.138281+00:00"}},"allNames":"revanex","offLabel":[],"synonyms":["revaprazan hydrochloride","revaprazan","revaprazan HCl","YH 1885","revanex","YH1885"],"timeline":[{"date":"2005-09-15","type":"positive","source":"DrugCentral","milestone":"Korean Food and Drug Administration (KFDA) approval"}],"brandName":"Revanex","ecosystem":[{"indication":"Duodenal ulcer disease","otherDrugs":[{"name":"algeldrate","slug":"algeldrate","company":"Sanofi Aventis Us"},{"name":"cimetidine","slug":"cimetidine","company":""},{"name":"famotidine","slug":"famotidine","company":"Valeant Pharms North"},{"name":"lansoprazole","slug":"lansoprazole","company":"Takeda Pharms Usa"}],"globalPrevalence":null},{"indication":"Gastric ulcer","otherDrugs":[{"name":"algeldrate","slug":"algeldrate","company":"Sanofi Aventis Us"},{"name":"cimetidine","slug":"cimetidine","company":""},{"name":"famotidine","slug":"famotidine","company":"Valeant Pharms North"},{"name":"lansoprazole","slug":"lansoprazole","company":"Takeda Pharms Usa"}],"globalPrevalence":null},{"indication":"Gastro-esophageal reflux disease with esophagitis","otherDrugs":[],"globalPrevalence":null}],"mechanism":{"target":"Potassium-transporting ATPase","targets":[{"gene":"ATP4A","source":"DrugCentral","target":"Potassium-transporting ATPase","protein":"Potassium-transporting ATPase alpha chain 1"},{"gene":"ATP4B","source":"DrugCentral","target":"Potassium-transporting ATPase","protein":"Potassium-transporting ATPase subunit beta"}],"modality":"Small Molecule","drugClass":"revaprazan","explanation":"","oneSentence":"","technicalDetail":"Revanex is a selective and reversible inhibitor of the gastric H+, K+-ATPase, which is the target enzyme responsible for acid secretion in the stomach."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/3525","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=REVAPRAZAN","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=REVAPRAZAN","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T02:43:57.741978","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:56:43.692206+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"dexlansoprazole","drugSlug":"dexlansoprazole","fdaApproval":"2009-01-30","patentExpiry":"Sep 27, 2026","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"esomeprazole","drugSlug":"esomeprazole","fdaApproval":"2001-02-20","patentExpiry":"Dec 8, 2036","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"lansoprazole","drugSlug":"lansoprazole","fdaApproval":"1995-05-10","patentExpiry":"Apr 21, 2036","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"omeprazole","drugSlug":"omeprazole","fdaApproval":"1989-09-14","patentExpiry":"Dec 8, 2036","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"pantoprazole","drugSlug":"pantoprazole","fdaApproval":"2000-02-02","patentExpiry":"Jun 7, 2026","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"rabeprazole","drugSlug":"rabeprazole","fdaApproval":"1999-08-19","genericCount":10,"patentStatus":"Off-patent — generic available","relationship":"same-target"}],"genericName":"revaprazan","indications":{"approved":[{"name":"Duodenal ulcer disease","source":"DrugCentral","snomedId":51868009,"regulator":"FDA"},{"name":"Gastric ulcer","source":"DrugCentral","snomedId":397825006,"regulator":"FDA"},{"name":"Gastro-esophageal reflux disease with esophagitis","source":"DrugCentral","snomedId":266433003,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"dexlansoprazole","brandName":"dexlansoprazole","genericName":"dexlansoprazole","approvalYear":"2009","relationship":"same-target"},{"drugId":"esomeprazole","brandName":"esomeprazole","genericName":"esomeprazole","approvalYear":"2001","relationship":"same-target"},{"drugId":"lansoprazole","brandName":"lansoprazole","genericName":"lansoprazole","approvalYear":"1995","relationship":"same-target"},{"drugId":"omeprazole","brandName":"omeprazole","genericName":"omeprazole","approvalYear":"1989","relationship":"same-target"},{"drugId":"pantoprazole","brandName":"pantoprazole","genericName":"pantoprazole","approvalYear":"2000","relationship":"same-target"},{"drugId":"rabeprazole","brandName":"rabeprazole","genericName":"rabeprazole","approvalYear":"1999","relationship":"same-target"}],"trialDetails":[{"nctId":"NCT07385235","phase":"PHASE1","title":"Compare and Evaluate the Safety and PK Data of a Single Dose Administration of 'AD-115A' or 'AD-1151'","status":"RECRUITING","sponsor":"Addpharma Inc.","startDate":"2026-01-27","conditions":["Gastric Ulcer"],"enrollment":46,"completionDate":"2026-03-16"},{"nctId":"NCT06902818","phase":"PHASE1","title":"The Study Compare and Evaluate the Safety and PK Data of a Single Dose Administration of 'AD-115A' or 'AD-1151'","status":"COMPLETED","sponsor":"Addpharma Inc.","startDate":"2025-03-21","conditions":["Gastric Ulcer"],"enrollment":46,"completionDate":"2025-05-08"},{"nctId":"NCT03378284","phase":"PHASE1","title":"A Study to Evaluate Safety, Tolerability, and PD of Tegoprazan on Healthy Male Volunteers","status":"COMPLETED","sponsor":"HK inno.N Corporation","startDate":"2017-12-10","conditions":["Pharmacodynamics","Healthy Male Volunteers"],"enrollment":16,"completionDate":"2018-01-16"},{"nctId":"NCT01750437","phase":"PHASE2","title":"Phase 2 Clinical Trial to Investigate the Safety, Tolerability and Efficacy of YH1885L in Patients With Non-erosive Reflux Disease(NERD)","status":"COMPLETED","sponsor":"Yuhan Corporation","startDate":"2013-01","conditions":["Non-erosive Reflux Disease"],"enrollment":149,"completionDate":"2014-04"},{"nctId":"NCT01332890","phase":"PHASE1","title":"Pharmacokinetic Drug Interaction Between Revaprazan and Itopride HCl in Healthy Male Subjects","status":"COMPLETED","sponsor":"Yuhan Corporation","startDate":"2011-04","conditions":["Healthy"],"enrollment":30,"completionDate":"2011-08"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"5P184180P5","CHEBI":"CHEBI:135529","INN_ID":"8415","UMLSCUI":"C2699073","chemblId":"CHEMBL1618279","ChEMBL_ID":"CHEMBL1618279","KEGG_DRUG":"D05722","DRUGBANK_ID":"DB16308","PUBCHEM_CID":"204104","IUPHAR_LIGAND_ID":"12007","SECONDARY_CAS_RN":"178307-42-1","MESH_SUPPLEMENTAL_RECORD_UI":"C108798"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":39,"therapeuticAreas":["Gastroenterology"],"biosimilarFilings":[],"recentPublications":[{"date":"2025 Dec","pmid":"41213274","title":"A Novel UPLC-MS/MS Method for Determining Tegoprazan in Rat Plasma: An Application in a Rat Pharmacokinetic Study.","journal":"Biomedical chromatography : BMC"},{"date":"2025 Nov 5","pmid":"41194018","title":"In vitro combination effects and mechanisms of Revaprazan with Triazole antifungal drugs on Aspergillus.","journal":"BMC microbiology"},{"date":"2025","pmid":"40697654","title":"Clinical pharmacokinetics of potassium competitive acid blockers: a systematic review and meta-analysis.","journal":"Frontiers in pharmacology"},{"date":"2025 Apr","pmid":"40296472","title":"Preliminary Analysis of Drug-Induced Ototoxicity in South Korea: Trends From a National Sample Dataset.","journal":"Journal of audiology & otology"},{"date":"2024 Apr-Jun","pmid":"41341971","title":"[Impact of P-CABs in the Treatment of Acid-related Diseases: an Evidence Review].","journal":"Acta gastroenterologica Latinoamericana"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:56:43.692206+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}